TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

WuXi Biologics Plans to Boost Manufacturing Capacity in Massachusetts

Tuesday, January 09, 2024

WuXi Biologics, a well-known Contract Research, Development, and Manufacturing Organization (CRDMO), has announced an expansion of its manufacturing capacity at its Worcester, Massachusetts facility to 36,000 liters. This decision comes in response to the increasing demand for contract manufacturing services worldwide. The MFG11 facility, currently under construction, will now raise its commercial drug substance capacity to 12,000 liters, exceeding the originally planned 24,000 liters. The facility, covering 189,500 square feet, has recently achieved weather-tight status and aims to be operational by 2025 with GMP release scheduled for 2026.

With over 400 employees in the U.S., WuXi Biologics expects to create an additional 200 jobs at the fully operational Worcester facility. Dr. Chris Chen, CEO of WuXi Biologics, emphasizes the strategic importance of the expanded capacity within their global biomanufacturing network. He underscores the company's dedication to enhancing capabilities to meet market and client needs, striving to offer more efficient and cost-effective manufacturing processes for the development of new biologics.

This expansion in Worcester follows the establishment of WuXi Biologics' first Boston Research Service Center last year, adding to its existing U.S. sites, including a clinical manufacturing facility in New Jersey and process development and characterization laboratories in Pennsylvania. With the Worcester facility expected to be fully operational by 2025, WuXi Biologics is positioned to provide comprehensive integrated services in the U.S., covering biologics discovery, development, and both clinical and commercial manufacturing.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit